Press Release
Arcadia Biosciences and Mahyco Announce Pipeline Advancement for Salinity Tolerant Rice
– Technology Can Help Mitigate the Impact of Salt Stress and Improve
Productivity in
In two years of initial field trials, rice varieties with Arcadia’s Salinity Tolerance (ST) trait showed double-digit yield increases under saline conditions with no loss of yield under normal conditions. Mahyco will be advancing these lead ST rice lines into their trait introgression program and conducting further multi-location field trials to validate trait performance, a significant step in product development and commercial advancement for both companies.
“With the conclusion of the salinity tolerant rice trials, we are able to identify lines which have shown superior performance in acute salt stress conditions,” said Dr. Usha Barwale Zehr, Chief Technology Officer of Mahyco. “We will now move forward to incorporate these rice lines into elite materials to bring commercial benefits to rice growers.”
The global cost of lost crop yield to salt-induced land degradation is
estimated to be
Arcadia’s Salinity Tolerance trait enables plants to produce increased yields under conditions of elevated salinity, expanding the range of usable acreage for crop production and reducing requirements for fresh water. Salinity Tolerant rice is in Phase 3 of development, and the trait has been applied other important row crops such as wheat and cotton.
Rice is the world’s most valuable crop, grown on more than 405 million
acres globally with a harvest value of
“This development signals an important milestone for us and our partner
Mahyco in terms of the additional value salt tolerance traits could have
on rice productivity,” said
About Mahyco
Established in 1964 by Dr.
About
Based in
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the company's Salinity Tolerance trait
and the regulatory process for such trait. Forward-looking statements
are subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered as
an indication of future performance. These risks and uncertainties
include, but are not limited to: the company’s and its partners’ and
affiliates’ ability to identify and isolate desired traits, including
Salinity Tolerance; the company’s and its partners’ ability to develop
commercial products incorporating its traits, including Salinity
Tolerance, and complete the regulatory review process for such products;
the company’s compliance with laws and regulations that impact the
company’s business, and changes to such laws and regulations; the
company’s future capital requirements and ability to satisfy its capital
needs; and the other risks set forth in the company’s filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160307005392/en/
Source:
Arcadia Biosciences
Jeff Bergau, +1-312-217-0419
jeff.bergau@arcadiabio.com
or
Maharashtra
Hybrid Seeds Co. Pvt. Ltd.
Subbarao Appemane, +91-22-6757-3000
subbarao.appemane@mahyco.com